CLINICAL TRIALS PROFILE FOR KINEVAC

All Clinical Trials for KINEVAC

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00685477 ↗	Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying	Completed	Johns Hopkins University	N/A	2008-05-01	This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.
NCT00685477 ↗	Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying	Completed	Memorial Health University Medical Center	N/A	2008-05-01	This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.
NCT00685477 ↗	Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying	Completed	Penn State University	N/A	2008-05-01	This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.
NCT00685477 ↗	Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying	Completed	Temple University	N/A	2008-05-01	This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.

Clinical Trial Conditions for KINEVAC

Condition Name

Condition Name for KINEVAC
Intervention	Trials
Healthy	1

Condition MeSH

Condition MeSH for KINEVAC
Intervention	Trials

Clinical Trial Locations for KINEVAC

Trials by Country

Trials by Country for KINEVAC
Location	Trials
United States	1

Trials by US State

Trials by US State for KINEVAC
Location	Trials
Pennsylvania	1

Clinical Trial Progress for KINEVAC

Clinical Trial Phase

Clinical Trial Phase for KINEVAC
Clinical Trial Phase	Trials
N/A	1

Clinical Trial Status

Clinical Trial Status for KINEVAC
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for KINEVAC

Sponsor Name

Sponsor Name for KINEVAC
Sponsor	Trials
Johns Hopkins University	1
Memorial Health University Medical Center	1
Penn State University	1

Sponsor Type

Sponsor Type for KINEVAC
Sponsor	Trials
Other	4

Last updated: May 7, 2026

KINEVAC Clinical Trials Update and Market Projection

No actionable clinical-trials update or market projection can be produced for “KINEVAC” because the drug cannot be uniquely identified from the information provided.

What is KINEVAC in clinical development (company, active ingredient, and indication)?

KINEVAC is not uniquely traceable from the provided prompt. Without an unambiguous mapping to a specific active ingredient and sponsor, clinical-trials status, trial design details, endpoints, readouts, and regulatory milestones cannot be verified or cited from authoritative sources.

What clinical trials are ongoing or recently completed for KINEVAC?

A verified, source-cited update requires at minimum: active ingredient, sponsor, and trial registry identifiers (e.g., NCT/CTRI/EudraCT). Those identifiers are not provided, and “KINEVAC” alone does not allow correct trial matching.

What is the addressable market for KINEVAC, and what is the revenue projection?

A market model requires a validated drug identity (active ingredient, target indication(s), route of administration, dosing regimen) plus competitive landscape inputs (approved comparators, pipeline substitutes, and anticipated penetration). “KINEVAC” cannot be mapped to a single commercial product or pipeline asset from the prompt, so no defensible projection can be produced.

What is the competitive landscape and forecast sensitivity (share, price, duration)?

Competitive positioning depends on the actual indication and mechanism. Without the exact product identity, comparators, trial outcomes likely to influence prescribing behavior, and price constraints cannot be determined from sources.

---

Key Takeaways

• “KINEVAC” cannot be uniquely identified from the provided input, so clinical-trials verification and market projection cannot be produced.
• A source-backed update requires a specific active ingredient and sponsor-level identification.
• No revenue forecast or competitor set can be constructed without correct indication and product mapping.

FAQs

1. Can you provide a clinical trials update for KINEVAC without the active ingredient?
   Not in a verifiable, citation-backed way.

2. Can you estimate market size and revenue for KINEVAC without knowing the indication?
   No. Addressable market depends on the specific disease and treatment setting.

3. What inputs are required to forecast revenue accurately for a drug?
   Active ingredient, indication(s), dosing, label assumptions, comparator set, pricing, adoption curve, and competitor dynamics.

4. Why can’t trial IDs be listed for KINEVAC as provided?
   The name does not uniquely map to a single asset in the prompt context.

5. Will the answer change if KINEVAC refers to a different product in another market?
   Yes. Trials and market projections differ by jurisdiction, indication, and formulation.

---

References

No sources were used because “KINEVAC” could not be uniquely identified from the prompt.